<DOC>
	<DOCNO>NCT00002213</DOCNO>
	<brief_summary>The purpose study see safe effective give 1592U89 plus 141W94 plus DMP 266 patient HIV develop resistance indinavir , ritonavir , saquinavir , nelfinavir least 20 week protease inhibitor treatment . This study also examine long combination therapy effective patient develop resistance .</brief_summary>
	<brief_title>The Safety Effectiveness 1592U89 Plus 141W94 Plus DMP 266 Patients With HIV Who Developed Resistance Protease Inhibitors</brief_title>
	<detailed_description>This multicenter , open-label study . A total 80 patient treat study include : At least 30 patient viral burden 500 - 40,000 copies/ml . At least 30 patient viral burden great 40,000 copies/ml . At least 20 patient less 1 year total prior treatment nucleoside reverse transcriptase inhibitor ( NRTIs ) . All patient receive self-administered , combination antiretroviral therapy 48 week , follow : 1592U89 plus 141W94 plus DMP 266 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Hematologic supportive therapy GMCSF , GCSF , erythropoietin . Drugs may interact CYP3A4 , use caution include ( limited ) : alprazolam , carbamazepine , codeine , cimetadine , clarithromycin , dapsone , diazepam , diltiazem , erythromycin , estrogens , fluvastatin , glucocorticoid , imipramine , itraconazole , ketoconazole , lidocaine , lovastatin , nifedipine , phenobarbital , phenytoin , quinidine , rifabutin , simvastatin , warfarin . Detoxification treatment include opiate agonist ( methadone , buprenorphine , etc . ) : Patients currently receive treatment enrol stable therapy . Patients must : HIV1 infection ( CDC clinical category allow ) . HIV1 RNA great 500 copies/ml measure 1 occasion within 14 day study drug administration . Signed , inform consent parent legal guardian patient 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malabsorption syndrome gastrointestinal dysfunction may interfere drug absorption render patient unable take oral medication . Active AIDSdefining opportunistic infection disease likely preclude patient study participation . Serious medical condition diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction , opinion investigator , would compromise safety patient . Concurrent Medication : Excluded : Immunomodulating agent , e.g. , corticosteroid , interleukin , thalidomide , anticytokine agent interferon . Cytotoxic chemotherapeutic agent ( except local treatment Kaposi 's sarcoma ) . Antioxidants . Foscarnet therapy therapy agent document activity HIV1 vitro . Medications interact 141W94 : terfenadine , astemizole , cisapride , triazolam , midazolam , ergotamine/dihydroergotaminecontaining regimen . Vitamin E supplement . Other investigational treatment ( treatment available Treatment IND expand access mechanism evaluate individual basis ) . Concurrent Treatment : Excluded : Anticipated need radiation therapy ( exception local treatment Kaposi 's sarcoma ) . Patients follow symptoms condition exclude : History clinically relevant hepatitis within previous six month . History lymphoma . Prior Medication : Excluded : Cytotoxic chemotherapeutic agent within 30 day study drug administration anticipate need treatment within next 48 week ( exception local treatment Kaposi 's sarcoma ) . Investigational HIV1 vaccine trial receipt dose vaccine within past 3 month . Immunomodulating agent systemic corticosteroid , interleukin , interferon within 30 day study drug administration . Exposure investigational agent 1592U89 , 141W94 , DMP 266 ( Sustiva ) . Prior Treatment : Excluded : Radiation therapy . Required : Treatment least 1 follow protease inhibitor ( PIs ) minimum 20 week prior screen : indinavir , ritonavir , saquinavir , and/or nelfinavir . Treatment combination PIs recent 12 week entry study ( Day 1 ) . Active alcohol illicit drug use likely interfere dose schedule compliance protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>VX 478</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
	<keyword>efavirenz</keyword>
</DOC>